CAVATAK

BIOLOGICAL2 trials

Sponsors

Viralytics

Conditions

Melanoma

Phase 1

Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)

CompletedNCT02307149

ViralyticsMelanoma

Start: 2015-05-05End: 2019-11-05Updated: 2023-01-17

Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)

CompletedNCT02565992

ViralyticsMelanoma

Start: 2015-12-17End: 2019-11-04Updated: 2023-01-17

Related Papers

Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma.

2023-01-1814 citations

Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study

Journal for ImmunoTherapy of Cancer2022-12-0123 citations

A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study.

2022-11-2929 citations

381 Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study

Regular and Young Investigator Award Abstracts2021-11-013 citations

Abstract CT139: Intratumoral oncolytic virus V937 in combination with pembrolizumab (pembro) in patients (pts) with advanced melanoma: Updated results from the phase 1b CAPRA study

Cancer Research2021-07-018 citations

Abstract CT114: The MITCI (Phase 1b) study: A novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients with or without previous immune checkpoint therapy treatment

Cancer Research2017-07-0129 citations

Activity of a novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients previously treated with anti-PD1 blockade therapy.

Journal of Clinical Oncology2017-05-2025 citations

Abstract CT021: Phase Ib study of a novel immunotherapy combination therapy of intralesional coxsackievirus A21 and systemic ipilimumab in patients with advanced melanoma

Cancer Research2016-07-153 citations